Denosumab after total hip arthroplasty – Authors' reply

Mohit M. Mahatma; Raveen L. Jayasuriya; David Hughes; Nigel Hoggard; Simon C. Buckley; Andrew Gordon; Andrew J. Hamer; Mohammed W. Tomouk; Robert M. Kerry; Richard Eastell; Jeremy M. Wilkinson

doi:10.1016/S2665-9913(21)00142-9

Denosumab after total hip arthroplasty – Authors' reply

Mohit M. Mahatma
, Raveen L. Jayasuriya
, David Hughes
, Nigel Hoggard
, Simon C. Buckley
, Andrew Gordon
, Andrew J. Hamer
, Mohammed W. Tomouk
, Robert M. Kerry
, Richard Eastell
, Jeremy M. Wilkinson

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e406-e407
Journal	The Lancet Rheumatology
Volume	3
Issue number	6
DOIs	https://doi.org/10.1016/S2665-9913(21)00142-9
Publication status	Published (VoR) - Jun 2021

Funding

RE declares grants from Alexion, Amgen, Immunodiagnostic Systems, Roche, and Nittobo; and personal fees from Amgen, Immunodiagnostic Systems, Roche, GlaxoSmithKline Nutrition, Mereo, Sandoz, Nittobo, AbbVie, Samsung, Haoma Medica, Elsevier, CL Bio, Foundation for the National Institutes of Health, Viking, University of California San Francisco, Biocon, and Lyramid, outside the submitted work. All authors report a grant from Amgen, in relation to the work discussed here.

Access to Document

10.1016/S2665-9913(21)00142-9

Cite this

@article{b5f259c9f6f543ec84b5a811ac109506,

title = "Denosumab after total hip arthroplasty – Authors' reply",

author = "Mahatma, \{Mohit M.\} and Jayasuriya, \{Raveen L.\} and David Hughes and Nigel Hoggard and Buckley, \{Simon C.\} and Andrew Gordon and Hamer, \{Andrew J.\} and Tomouk, \{Mohammed W.\} and Kerry, \{Robert M.\} and Richard Eastell and Wilkinson, \{Jeremy M.\}",

note = "Funding Information: RE declares grants from Alexion, Amgen, Immunodiagnostic Systems, Roche, and Nittobo; and personal fees from Amgen, Immunodiagnostic Systems, Roche, GlaxoSmithKline Nutrition, Mereo, Sandoz, Nittobo, AbbVie, Samsung, Haoma Medica, Elsevier, CL Bio, Foundation for the National Institutes of Health, Viking, University of California San Francisco, Biocon, and Lyramid, outside the submitted work. All authors report a grant from Amgen, in relation to the work discussed here.",

year = "2021",

month = jun,

doi = "10.1016/S2665-9913(21)00142-9",

language = "English",

volume = "3",

pages = "e406--e407",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Denosumab after total hip arthroplasty – Authors' reply

AU - Mahatma, Mohit M.

AU - Jayasuriya, Raveen L.

AU - Hughes, David

AU - Hoggard, Nigel

AU - Buckley, Simon C.

AU - Gordon, Andrew

AU - Hamer, Andrew J.

AU - Tomouk, Mohammed W.

AU - Kerry, Robert M.

AU - Eastell, Richard

AU - Wilkinson, Jeremy M.

N1 - Funding Information: RE declares grants from Alexion, Amgen, Immunodiagnostic Systems, Roche, and Nittobo; and personal fees from Amgen, Immunodiagnostic Systems, Roche, GlaxoSmithKline Nutrition, Mereo, Sandoz, Nittobo, AbbVie, Samsung, Haoma Medica, Elsevier, CL Bio, Foundation for the National Institutes of Health, Viking, University of California San Francisco, Biocon, and Lyramid, outside the submitted work. All authors report a grant from Amgen, in relation to the work discussed here.

PY - 2021/6

Y1 - 2021/6

UR - https://www.scopus.com/pages/publications/85106569932

UR - https://www.scopus.com/pages/publications/85106569932#tab=citedBy

U2 - 10.1016/S2665-9913(21)00142-9

DO - 10.1016/S2665-9913(21)00142-9

M3 - Letter

AN - SCOPUS:85106569932

SN - 2665-9913

VL - 3

SP - e406-e407

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 6

ER -

Denosumab after total hip arthroplasty – Authors' reply

Funding

Access to Document

Other files and links

Cite this